These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Results of the VIGOR study. Rofecoxib halves the complication rate]. MMW Fortschr Med; 2001 Jun; 143(23):35. PubMed ID: 11460417 [No Abstract] [Full Text] [Related]
3. Rofecoxib-induced pseudoporphyria. Markus R; Reddick ME; Rubenstein MC J Am Acad Dermatol; 2004 Apr; 50(4):647-8. PubMed ID: 15034522 [No Abstract] [Full Text] [Related]
4. Rofecoxib and inflammatory bowel disease: clinical and pathologic observations. Wilcox GM; Mattia AR J Clin Gastroenterol; 2005 Feb; 39(2):142-3. PubMed ID: 15681911 [TBL] [Abstract][Full Text] [Related]
5. Tolerance induction to rofecoxib in a patient with Bartter's syndrome. Nucera E; Schiavino D; Pollastrini E; Manna R; Di Lillo M; Buonomo A; Roncallo C; Patriarca G Allergy; 2004 Jul; 59(7):788-9. PubMed ID: 15180770 [No Abstract] [Full Text] [Related]
6. Intracranial hypertension induced by rofecoxib. Jacob S; Rajabally YA Headache; 2005 Jan; 45(1):75-6. PubMed ID: 15663617 [TBL] [Abstract][Full Text] [Related]
8. [Really only Vioxx?]. Heinzl S Med Monatsschr Pharm; 2004 Nov; 27(11):361. PubMed ID: 15566229 [No Abstract] [Full Text] [Related]
9. Rofecoxib-associated upper gastrointestinal bleed: a case report. Freedman GM; Kreitzer JM; Badola R Mt Sinai J Med; 2002; 69(1-2):105-6. PubMed ID: 11832981 [TBL] [Abstract][Full Text] [Related]
10. [Withdrawal of rofecoxib: a sign to be careful with coxibs in patients with increased cardiovascular risk]. Bijlsma JW Ned Tijdschr Geneeskd; 2004 Oct; 148(44):2162-4. PubMed ID: 15559407 [TBL] [Abstract][Full Text] [Related]
11. Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial. Biancone L; Tosti C; Geremia A; Fina D; Petruzziello C; Emerenziani S; Pallone F Aliment Pharmacol Ther; 2004 Apr; 19(7):755-64. PubMed ID: 15043516 [TBL] [Abstract][Full Text] [Related]
12. Adverse oral reactions associated with the COX-2 inhibitor rofecoxib. Bagán JV; Thongprasom K; Scully C Oral Dis; 2004 Nov; 10(6):401-3. PubMed ID: 15533219 [TBL] [Abstract][Full Text] [Related]
13. Severe cholestasis and acute renal failure related to rofecoxib. Linares P; Vivas S; Jorquera F; Olcoz JL; de Leon B; Oritz de Urbina J Am J Gastroenterol; 2004 Aug; 99(8):1622-3. PubMed ID: 15307886 [No Abstract] [Full Text] [Related]
14. The trade-off between cardiovascular and gastrointestinal effects of rofecoxib. Florentinus SR; Heerdink ER; de Boer A; van Dijk L; Leufkens HG Pharmacoepidemiol Drug Saf; 2005 Jul; 14(7):437-41. PubMed ID: 15937867 [TBL] [Abstract][Full Text] [Related]
15. Factors associated with celecoxib and rofecoxib utilization. Rawson NS; Nourjah P; Grosser SC; Graham DJ Ann Pharmacother; 2005 Apr; 39(4):597-602. PubMed ID: 15755796 [TBL] [Abstract][Full Text] [Related]
16. [Acute ulcerative colitis in a patient treated with rofecoxib who took aspirin as self-medication]. Charachon A; Petit T; Lamarque D; Soulé JC Gastroenterol Clin Biol; 2003 May; 27(5):511-3. PubMed ID: 12843913 [No Abstract] [Full Text] [Related]
19. High frequency of use of rofecoxib at greater than recommended doses: cause for concern. Griffin MR; Stein CM; Graham DJ; Daugherty JR; Arbogast PG; Ray WA Pharmacoepidemiol Drug Saf; 2004 Jun; 13(6):339-43. PubMed ID: 15170762 [TBL] [Abstract][Full Text] [Related]
20. A double-blind prospective comparison of rofecoxib vs ketorolac in reducing postoperative pain after arthroscopic knee surgery. Kim JT; Sherman O; Cuff G; Leibovits A; Wajda M; Bekker AY J Clin Anesth; 2005 Sep; 17(6):439-43. PubMed ID: 16171664 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]